Genetic signatures of bipolar disorder course specifiers

Tracey van der Veen[2], Nick Bass[2], Andrew McQuillin[2]

[2]Molecular Psychiatry Laboratory, Division of Psychiatry, University College London,

London, UK

Abstract

Background: Bipolar disorder (BD) presents with complex clinical features. While factor models have elucidated dimensional psychopathology in BD, they have overlooked the interplay between premorbid psychosocial deficits, long-term outcomes, and transdiagnostic genetic influences. Identifying these underlying dimensions is crucial for personalised interventions. **Aims:** This observational study aimed to identify a comprehensive dimensional model of BD psychopathology **integrating premorbid psychosocial deficits and poorer outcomes (reduced inter-episode remission, chronicity)**, to investigate their association with the genetic burden of BD and related transdiagnostic disorders, schizophrenia (SCZ), major depression (MDD), attention-deficit and hyperactivity disorder (ADHD), and anxiety (ANX). We hypothesised, psychosocial deficits correlate with worse BD outcomes. **Method:** We employed Inverse Probability Weighting (IPW) on a sample of 4992 participants to minimise bias. Exploratory Factor Analysis (EFA) of 77 OPCRIT items identified four symptom dimensions. Confirmatory Factor Analysis (CFA) validated a 20-item, four-factor model. Polygenic Risk Scores (PRSs) for five psychiatric disorders were calculated, and Structural Equation Modelling (SEM) was used to analyse genetic contributions to these dimensions. **Results:** The CFA demonstrated a good fit for the four-factor model, comprising 'mania,' 'psychosis,' 'depression,' and a **novel 'psychosocial functioning' dimension**. SEM revealed distinct genetic liabilities: BD PRS primarily predicted 'mania,' SCZ PRS 'psychosis,' and MDD PRS 'depression.' **Notably, the 'psychosocial functioning' dimension, characterised by premorbid psychosocial deficits and poorer outcomes, showed positive associations with ADHD and anxiety PRSs, and an inverse correlation with BD PRS. Conclusions: This study provides a novel dimensional model of BD that integrates premorbid psychosocial factors and outcomes, revealing a link between genetic burden of ADHD and anxiety with a 'psychosocial functioning' dimension associated with poorer BD outcomes.** This suggests a biological basis for the complex interplay between factors, highlighting the potential for early identification and targeted interventions for individuals at higher risk for a more challenging illness trajectory.

Key terms: bipolar disorder, ADHD, anxiety, psychosocial, dimensions, polygenic risk scores

Introduction

Heterogeneity in BD

Outcomes in bipolar disorder (BD) are highly variable. Current BD subtypes, type 1 (BD1) and type 2 (BD2), have distinct diagnostic criteria, but they exhibit significant clinical variability due to underlying genetic differences. This clinical variability is not fully captured by current classification systems, such as the DSM-5[1] and OPCRIT[2] . While utilising additional course specifiers (such as anxious distress, rapid cycling, psychotic features, and varying functional impairments to improve treatment alignment), they do not fully address the spectrum of presentations.

Continuum of symptoms

Beyond the discrete episodes of mania and depression defined by diagnostic criteria, many patients with BD experience a continuum of symptoms. Indeed, many patients (50–70%) experience cognitive deficits during these periods, which can lead to psychosocial challenges.[3] Furthermore, 20–50% of individuals report inter-episodic symptoms.[4] Even during euthymic periods, individuals may experience executive dysfunction and increased anxiety.[5] Personality traits have also been shown to affect the disorder's onset and progression.[6]

Homogeneous subgroups in BD

Research is increasingly focusing on identifying genetic differences in more homogeneous subgroups to understand the genetic factors behind the diverse clinical presentations in subtypes. Several BD course specifiers have been recognised as genetically homogeneous subgroups and evidence of familiality.[7-14] Most research, however, only examines specifiers in single regression models, complicating interpretation. **A dimensional framework offers a powerful alternative, as it can examine how these specifiers are interrelated and estimate their combined genetic liabilities simultaneously for a more accurate, holistic analysis.[12-20]**

Course specifiers

Two critical factors that contribute to the variability in BD and are not fully recognised as specifiers in the DSM-5[1] are cognitive and psychosocial deficits. Cognitive impairments, affecting attention, memory, executive functions, emotion regulation, and decision-making, significantly impact outcomes including quality of life (QoL).[21] The severity of these impairments is closely linked to psychosocial deficits, even during periods of relative mood stability.[22] Psychosocial deficits, existing on a spectrum, negatively affect relationships, work, school productivity, and can lead to social withdrawal. Impairments in psychosocial functioning have been reported in 30–60% of adults with BD.[23] Early onset of these deficits is linked to a higher risk of mood disorders and worse overall outcomes, including anxiety, substance use disorders, and suicidality.[24] Children with psychosocial and cognitive deficits are more likely to experience suicidality.[25] Timely recognition of the genetic predisposition of these outcomes could reduce prolonged disability due to diagnostic delays of up to seven years[26] and help lower the 5-20% rate of completed suicides.[27]

Genetic contributions to BD heterogeneity

Genetic contributions also play a role in the high rates of comorbidity observed in BD.[28] Around 65% of individuals with BD have at least one additional psychiatric condition, such as ADHD, anxiety, or personality disorders.[29] Symptoms of these comorbidities can begin in childhood and continue into adulthood, potentially worsened by environmental factors.[30-34] Polygenic risk scores (PRS), reflecting the combined impact of common genetic variants, offer a tool to investigate this genetic influence. For instance, a higher PRS for SCZ demonstrated a greater risk of incongruent-psychosis and an earlier onset of BD.[12,14] A PRS for ADHD or anxiety correlated with rapid cycling, considered a chronic form of the disorder.[9,35-36] ADHD increases the likelihood of multimorbidity and can worsen BD symptoms.[37-39] Polygenic ADHD burden in BD has also been linked to earlier age of onset and lithium resistance, while lithium response can be influenced by family history and the absence of anxiety or rapid cycling.[40-43] **Factor analysis can simplify these complex relationships, revealing core factors and their interconnected genetic contributions.**

Clinical dimension models

A prior study created a three-factor model of BD clinical dimensions using OPCRIT items specific to mania, psychosis, and depression, revealing distinct genetic signatures for each dimension.[44] The current

study extends this by increasing the number of OPCRIT items and PRS to explore genetic contributions in premorbid BD course specifiers. We hypothesised and found that premorbid psychosocial deficits (social, occupational, and personality) and BD outcomes (reduced inter-episode remission and chronic course) correlated and shared genetic burdens for ADHD and anxiety. **This research aims to demonstrate the utility of a dimensional framework in identifying genetically homogeneous dimensions for future research, classifications, early interventions, and therapeutic treatments.**

Methods

Study Design and Materials

This study used cross-sectional data to examine the relationships between clinical symptoms and genotypes linked to bipolar disorder, schizophrenia, depression, anxiety, and ADHD. Written informed consent was obtained from all participants. Research psychologists or psychiatrists conducted semi-structured interviews using the 90-item OPCRIT with bipolar disorder patients. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and **with the Helsinki Declaration of 1975, as revised in 2013.** All procedures involving human subjects/patients were approved by the NHS Metropolitan Multi-centre Research Ethics Committee (MREC/03/11/090).

Participants

Genotype data from 4992 individuals was analysed after quality control measures. Clinical symptoms were assessed in 2590 individuals diagnosed with bipolar disorder using DSM-IV criteria, including BD1, BD2, BD-NOS (not-otherwise-specified), or schizoaffective disorder bipolar type. The age of onset for BD was determined based on the first occurrence of manic, mixed, or major depressive episodes. Most healthy controls were screened random blood donors, with 13% excluded from screening for psychiatric disorders.

Polygenic risk Score profiling

Genotyping of the participants was performed at the Broad Institute using the Affymetrix Gene Chip 500k Assay, Illumina PsychArray, and Illumina Global Screening Array (GSA). Variants and individuals not meeting quality control were removed. The median number of post-QC variants was 3,164,648, which was used for polygenic risk score (PRS) analysis with imputed dosage files, genome-wide summary statistics for each psychiatric disorder and a linkage disequilibrium (LD) reference panel. Continuous-shrinkage PRS (PRS-CS-Auto) software in a Bayesian framework, using the default automatic shrinkage setting, calculated five trait PRS for each participant. Summary statistics from the largest, most recent genome-wide association study (GWAS) for BD, depression, schizophrenia, anxiety, and ADHD were utilised. PLINK v2.0 generated individual-level PRS scores.

Controlling for observational study biases

Accurate interpretation and generalisation of the results require adjustments for potential confounders. Hospitalised cases, reported in (OPCRIT 1 'Source of rating'), often exhibit more severe symptoms and worse outcomes, which may be linked to a higher genetic burden. To adjust for these confounders in the PRS analyses, we used Inverse Probability Weighting (IPW) to construct a propensity score for both cases and controls.[45] This method enables a more reliable comparison of genetic risk across groups from the same ancestry, by accounting for their propensity for inclusion in the study and symptom severity. This can reduce false associations between PRS and outcomes associated with observational study data, which is not randomly assigned, producing systematic differences between groups (e.g., cases and controls or between cases with different symptoms). Stabilised weights were applied to limit the influence of extreme weights in the analyses. Additional covariates of sex, genetic ancestry and genotyping array were included together with IPW propensity scores (see supplementary S14-15) to calculate a more meaningful propensity score. Additionally, we conducted sensitivity analyses to confirm the robustness of the results.[46-47]

Statistical analyses

A priori power analyses were conducted (supplementary S1). Statistical analyses were performed using EFA with 77 OPCRIT items while keeping sample sizes adequate and minimising missing data to 8%. The clinical dataset was split into 60% in the EFA and 40% for the subsequent CFA. The same split was applied in the sensitivity analyses using individuals' factor or polygenic risk scores. SEM used the full sample as did the robustness check for factor loadings below the .6 cutoff. The strongest OPCRIT items were identified in the EFA, and 20 items with a median loading of .6 or higher across dimensions were carried forward to the CFA. The 'WLSMV' setting and 'geomin' selection were applied due to the items' natural order and correlation. **Four dimensions were confirmed in the CFA, validated by the scree plot, parallel analysis, and the lowest Root Mean Square Error of Approximation (RMSEA) in the EFA (S3-5). The Multiple Indicator Multiple Cause (MIMIC) SEM model was used to test the genetic burdens of the four CFA dimensions with five PRS.[48]** Regressions were replicated outside the SEM to check for multicollinearity, revealing minimal multicollinearity or redundancy among the five psychiatric PRS, with a median (interquartile range, IQR) variance inflation factor (VIF) of 1.079(1.074,1.087) in models predicting the dimensions.

Sensitivity analyses

To test the sensitivity of the EFA factor loadings, we assessed the predictability of items with a cutoff of .4 instead of .6, based on a previous three-factor model (mania, psychosis, depression).[44] The EFA model's item loadings, also chosen for clinical relevance and complexity, would be expected to align with existing findings, which occurred as expected.[49] For example, rapid cycling and substance use disorders correlated with items in the psychosocial dimension, which supported the internal reliability of lower factor loadings in the novel 'psychosocial' dimension.[50-51]

Two additional sensitivity analyses assessed the robustness of the results using factor and PRS scores. For more details on the methods, including these additional checks, see supplementary S1. All factor and statistical analyses were performed in R(version 4.4.2), using the Lavaan package together with the Bonferroni correction criteria, used to correct for multiple testing.[52-53]

Results

(i) Clinical Characteristics

We examined 77 clinical symptoms and estimated five psychiatric disorder PRS in 2590 individuals with BD and 2402 controls. The sample consisted of 61% females and 39% males, with no sex distribution differences across BD subtypes ($\chi^2(2, N=2{,}194) = 2.212$, $p > .05$). A difference in age of onset was found across BD subtypes ($\chi^2(2) = 8.204$, $p = 0.016$), between schizoaffective bipolar type (SZA) and BD2 in Wilcoxon rank sum tests (Table 1).

(ii) EFA We evaluated 77 clinical symptoms in a calibration sample of 1554 BD patients, representing 60% of the cohort. 76 symptoms loaded ($p \leq .05$) across at least one of four identified factors; 'Family history of schizophrenia' (OPCRIT 13) was the exception. Symptoms exceeding .4 were first visualised based on factor loadings (supplementary S6). **A four-factor EFA model fit the data best, with χ^2 = 304 and RMSEA = .033 (90% CI .024–.037), CFI = .989, and TLI = .986 (**supplementary **S3). The retention of four factors (dimensions) was validated by the scree plot, parallel analysis (**supplementary **S4-5) and the lower RMSEA for 4-factor EFA model relative to the 1-3 factor models (**supplementary **S2-3).**

(iii) CFA We identified items with a median threshold of .6 for EFA factor loadings to each of the four dimensions, to ensure a parsimonious CFA model with items which were also checked for clinical relevance in the literature. The 20 core symptoms formed a four-factor model, validated through CFA. The results of the 4-factor CFA model using 20 clinical symptoms indicate a good fit to the data: $\chi2 = 505.88$, RMSEA = .03 [.03, .04], CFI = .99, TLI = .99 (supplementary S8). As each factor was defined by OPCRIT items with the highest EFA loadings, the factors demonstrated robust associations ($p < .05$) with all 20 symptoms (supplementary S9). **The CFA function generated a four-factor model with interrelated 'mania', 'psychosis', 'depression', and 'psychosocial functioning' symptom dimensions (**supplementary **S8-9).** As expected, lower covariances between dimensions compared to dimension items indicated that the analysis identified distinct structures in the dimensions with minimal overlap; mania to psychosis, .269, mania to depression, .240, and mania to the psychosocial dimension, -.165.

(iv) SEM (MIMIC) indicated distinct genetic liabilities across the four clinical dimensions (Figure 1). The mania dimension, strongest associated with BD PRS, associated positively with psychosis and depression, and inversely with psychosocial symptoms which correlated with worse outcomes. The PRS, as expected, correlated strongest with their symptom dimensions; SCZ with psychosis, BD with mania, MDD with depression, and ADHD and anxiety with the novel psychosocial dimension (supplementary S10). The MIMIC model fit the data well but with less reliability than the CFA. The 4-factor Structural Equation Model (SEM) with MIMIC variables, using 20 clinical symptoms and five PRS, demonstrated an acceptable fit to the data: $\chi 2 = 348.45$, RMSEA = .04 [.04, .04], CFI = .92, TLI = .90. (Figure 1).

(v) Sensitivity analyses

Individual-level factor (dimension) scores To analyse each of the 20 core item's independent contribution to the CFA model, we performed regression analyses using individual-level factor scores, which captured each participant's relationship to each of the four dimensions. Factor scores were estimated using a series of CFA 'leave-one-out' analyses, excluding one of the 20 symptoms in each dimension in turn. The median RMSEA of the 'leave one out' CFAs remained relatively stable, median(IQR) was .369(.317,.403) within the confidence intervals of the full CFA model (supplementary S8). This indicated a robust model that was not overly dependent on one of the 20 core items. The 20 items were each predicted by one of the individual-level factor scores for each dimension in turn. Participants in the top 10% of scores were more likely to report the symptom compared to those in the lower 90%. Their factor score for the symptom-related dimension was a better predictor than scores from other dimensions (Figure 2, supplementary S11). The odds of reporting 'mania' symptoms were, 1.531-1.778 (CI 95%, 1.361-2.156), 1.443-1.962 (CI 95%, 1.672 -2.541) for 'psychotic' features, 1.348-2.268 (CI 95%, 1.247 -2.990) for 'depression' symptoms, and 1.497-3.013 (CI 95%, 1.293-4.287) for premorbid 'psychosocial deficits', reduced inter-episode remission or chronicity.

Individuals' PRS Scores

To ensure the genetic contributions at the global SEM level held for each dimension item, we performed regression analyses using each item and individual-level PRS scores in turn. Participants with the top 10% compared to the lower 90% of scores for the respective dimension, were associated with a higher risk for dimension-related symptoms (Figure 3, supplementary S12); SCZ PRS increased the odds of psychotic features, 1.254 -2.003 (CI 95%, 1.240 - 2.027), BD PRS for mania 1.317-1.453 (CI 95%, 1.225 - 1.556), MDD PRS for depression 1.063- 1.134 (CI 95%, 1.037 - 1.163) and **ADHD PRS 1.041-1.409 (CI 95%, 1.026 - 1.425) for psychosocial deficits, reduced inter-episode remission or chronicity.** Separation of the global effects revealed a mixture of effect directions related to ANX and the SCZ PRS for the psychosocial dimensions.

(vi) *Post hoc* Regression Analyses

Rapid cycling (RC) which is considered a chronic form of BD[36], would be expected to correlate with the psychosocial dimension symptoms (see item description supplementary S13), indicating the reliability of the novel dimension. Indeed, RC positively associated here with the psychosocial dimension in the EFA, below the .6 cutoff for CFA, and inversely to mania (supplementary S7). Also, RC showed a positive association with premorbid social functioning (OR 1.185, 95% CI 1.110–1.243, $P = 1.04 \times 10^{\square\square}$) and personality disorders (OR 1.391, 95% CI 1.287–1.512, $P = 1.288 \times 10^{\square\square}$). Substance use disorder is linked to psychosocial functioning.[54] Premorbid personality disorder associated here with substance abuse (OPCRIT 80) (OR 1.160, 95% CI 1.129–1.203, $P = 4.98 \times 10^{\square\square}$) and suicidal ideation (OPCRIT 43) (OR 1.140, 95% CI 1.113–1.207, $P = 1.28 \times 10^{\square\square}$). Both personality disorder and RC associated with a higher ADHD PRS (1.325, $P = 6.14 \times 10^{\square\square}$) and (OR 1.209, $P = 4.78 \times 10^{\square\square}$), and an earlier onset of BD ($F(1,2011) = -3.782$, $P = 6.46 \times 10^{\square\square}$) and ($F(1,1256) = -3.026$, $P = 4.821 \times 10^{\square\square}$) respectively.

Table 1. Participant's characteristics stratified by bipolar disorder subtypes

		Bipolar disorder subtypes			
Catergory	**Overall**, *N* = 2,590[1]	**SZA**, *N* = 332[1]	**BD1**, *N* = 1,475[1]	**BD2**, *N* = 387[1]	*p*-value[2]
BD Age Onset	26 (11)	25 (9)	26 (11)	28 (11)	2.1e-04
Sex -					2.6e-01
Female	61% (1,333 / 2,194)	59% (197 / 332)	62% (913 / 1,475)	58% (223 / 387)	
Male	39% (861 / 2,194)	41% (135 / 332)	38% (562 / 1,475)	42% (164 / 387)	
Age interviewed	49 (13)	46 (12)	49 (13)	51 (14)	3.1e-07

[1] Median (IQR) or Frequency (%)

[2] Kruskal-Wallis rank sum test; Pearson's Chi-squared test

Abbreviations: bipolar disorder subtype 1 (BD1), bipolar disorder subtype 2 (BD2), bipolar disorder not-otherwise-specified (BD-NOS), or schizoaffective disorder bipolar type (SZA)
NOS (Not Otherwise Specified) =*N*, 192. Unknown=*N*, 204.



Model	Chi.sq	RMSEA	CI.lower	CI.upper	CFI	TLI
4-factor	348.45	.04	0.04	0.04	.92	.90

Note. The data was extracted from the 4-factor SEM (MIMIC) model using 20 clinical symptoms and five PRS.

Figure 1. Structural equation (MIMIC) model (SEM) path diagram and fit indices

Rectangles represent the five PRS, the circles indicate the four dimensions, and the squares are the item numbers listed in the EFA (supplementary S7). See supplementary S9 for the OPCRIT item numbers. Arrows on the left-hand side represent associations between the PRS and the four (factor) dimensions. Arrows on the right-hand side are representative of associations between the dimensions and the OPCRIT items. The values on the RHS between dimensions (circles) are the covariances between the mania dimension and the other three dimensions.



Figure 2. **Core OPCRIT items associations using individuals' leave-one-out factor scores** The odds ratio (OR) and 95% confidence intervals represent the strength of association (x-axis) between the 20 core items (y-axis) using participants' factor scores for one of the four factor dimensions (individuals with the 10% scores compared to the remaining 90% of scores). Each point reflects a logistic regression model adjusted for inclusion propensity, age, age-squared and sex. An OR greater than 1 indicated an increased risk of the symptom, an OR less than 1 represented a decreased risk. The shapes denote the different (factor) dimensions. Hollow points represent tests that did not surpass the Bonferroni correction criteria.



Figure 3. Core OPCRIT predictions using five transdiagnostic individual-level PRS scores The odds ratio (OR) and 95% confidence intervals represent the strength of association (x-axis) between the 20 core items (y-axis) as a function of the bipolar disorder participants' five PRS scores (individuals with the 10% compared to the remaining 90% of scores). Each point reflects a logistic regression model for one core item, adjusted for inclusion propensity, age, age-squared, sex, genetic ancestry and genotype array. An OR greater than 1 indicated an increased risk of the item, while an OR less than 1 represented a decreased risk. The shapes denote the different transdiagnostic PRS. Hollow points represent tests that did not surpass the Bonferroni correction criteria.

Discussion

The MIMIC (Multiple Indicator Multiple Cause) model, a novel four-factor structure of bipolar disorder (BD)'s genetic architecture, uniquely incorporates transdiagnostic genetic risk on core symptoms and a 'psychosocial' dimension linked to poorer outcomes. This is the first model linking a genetically influenced 'psychosocial' dimension connecting premorbid deficits and adverse long-term outcomes (chronicity, reduced inter-episode remission) to genetic risk for ADHD and anxiety. This research uniquely shows genetic tendencies for ADHD and anxiety contribute to core difficulties in social functioning, work, personality, and a less stable BD course. **Identifying this 'psychosocial' dimension and its genetic links offers a new understanding of challenges beyond mood episodes in BD. This suggests a biological basis emphasising transdiagnostic risks in the spectrum of BD and its variable outcomes.**

Four versus a Three-Factor Model

Building on dimensional approaches in psychiatry, our study used more OPCRIT measures than a prior study, yielding a fourth 'psychosocial' dimension, validated in both our and their parallel analysis (eResults 4).[44] We confirmed three clinical dimensions (mania, depression, psychosis) and their genetic associations. Importantly, added symptoms (supplementary **S13) and PRS loaded exclusively on our novel psychosocial dimension. Thus, a four-factor model better accounts for genetic signatures in BD course specifiers.** Additionally, our propensity scores adjusted for potentially inflated effect sizes.

Predictive Utility of the PRS

Sensitivity analyses confirmed symptom strength independent of global dimensions. Factor and PRS scores predicted risk for four dimension symptoms better within than across dimensions in unseen data. However, limited PRS power provided minimal added predictive value to clinical data, with median positive prediction value (PPV) below the (0.8) clinical utility threshold.[14,55]

Factor Loading Thresholds

We set a factor loading threshold of (0.6) for OPCRIT items for clinical relevance and parsimony, though past analyses used lower thresholds.[16, 44, 56] EFA robustness at (0.4) suggests a lower threshold for future studies. While model fit and sensitivity were adequate, more items do not ensure better accuracy and risk overfitting, reducing generalisability.

Genetics of the 'Psychosocial' Dimension

The novel 'psychosocial' dimension showed distinct genetic signatures. Higher BD burden showed some resilience against premorbid psychosocial deficits and chronic illness progression, predicting higher functioning in an independent BD data[57] and inversely related to rapid cycling.[9] Likewise, the mania dimension positively associated with BD PRS, was also inversely related to the psychosocial dimension. Further research on these negative signatures will be required.

Genetics of the 'Psychosocial' Dimension Symptoms

Symptoms BD and SCZ PRS linked to higher inter-episode remission, unlike MDD, ANX, and especially ADHD, positively associated with reduced inter-episode remission. Higher BD-PRS predicted inter-episode remission and reduced anxiety in independent BD data.[57] Depression, anxiety, and cognitive issues are often early BD symptoms.[58] Rapid cycling (RC) correlated with higher ANX or ADHD PRS but inversely with BD in a prior study.[9] ADHD and anxiety co-occurrence was previously shown to raise BD risk and poor outcomes.[59] Severe incapacity (OPCRIT 87) linked primarily to mania and psychotic features, less to psychosocial symptoms, and least to depressive symptoms (supplementary S7). BD PRS correlated with increased incapacity and lower depression polygenic burden in multiplex BD families.[60] Positive associations existed between premorbid social (OPCRIT 9) and occupational adjustment (OCPRIT 10) and ADHD, stronger with SCZ. Longitudinal data suggests enduring psychosocial and cognitive deficits in BD.[61] Psychosocial impairments affect (30-60)% of adults with BD, especially with comorbid anxiety and ADHD.[23]

Sensitivity analysis showed ADHD PRS consistently positive with the 'psychosocial' dimension, while ANX and SCZ PRS effects were more complex across indicators, suggesting nuanced relationships needing further granular investigation. **ADHD PRS positively associated with all psychosocial dimension symptoms.**

The higher BD1 proportion of cases, linked to lower anxiety, might have limited ANX PRS and psychosocial dimension item-level associations.[57] Prior factor analyses found the largest BD subgroup to be characterised by affective stability with low anxiety and low risk for ADHD-like behaviours, supporting our genetic findings.[62] **ADHD PRS uniquely correlated here to a higher risk for premorbid personality disorders (OPCRIT 11) and the other psychosocial dimension symptoms. ADHD and BD comorbidity has been shown to increase risk for personality disorder and more frequent episodes, leading to poorer functioning.[63] Childhood ADHD is significantly associated with higher borderline personality disorder (BPD) risk.[64]**

Implications for Clinical Practice

These findings have clinical implications. Children of parents with BD are at higher risk for ADHD and anxiety, negatively impacting outcomes if they also have BD.[65] Identifying genetic risks could aid early detection of psychosocial issues linked to higher suicidality risk.[66] Early ADHD and anxiety co-occurrence significantly increases complex BD phenotype risk and may predispose to rapid cycling, associated here as elsewhere with premorbid personality disorders and lifetime suicide attempts.[67-68]

Limitations

The study design addresses some but not all biases. Eurocentric genetic study biases limit PRS generalisability across ancestries. Single-timepoint lifetime psychopathology assessment limits causal conclusions and may include recall bias. PRS do not account for gene-environment interactions, non-genetic factors, natural selection, or assortative mating. Propensity scores work best with all known disease incidence factors.

Future Studies

Future research should validate the four-factor model's reproducibility across ancestral datasets preferably using the same or similar OPCRIT items. Also, longitudinal data is required. By tracking individuals over time, it can help establish the temporal order of events. While the environment doesn't change our underlying genetic code, it can influence how those genes are expressed (epigenetics) and interact to increase or decrease the likelihood of developing bipolar disorder. If genetic risk (as measured by PRS at baseline) precedes the environmental exposure or the onset of specific symptoms, it strengthens the inference that the PRS might be influencing these factors, rather than the other way around. Investigating how ADHD and anxiety trigger or exacerbate mood episodes in BD, especially in rapid cycling, could be a logical next step (e.g., neuroimaging or neurochemical studies). Longitudinal data with symptom scales could identify temporal links and triggers, especially targeting those at risk of suicidality.

Conclusion

Our analysis indicates a broader transdiagnostic signature may worsen outcomes due to psychosocial and cognitive deficits, particularly linked to higher ADHD and ANX PRS. The MIMIC model revealed an inverse relationship between mania and 'psychosocial functioning'. While ADHD PRS showed consistent positive association with 'psychosocial' dimension, ANX and SCZ PRS effects were more complex at the item level, contrasting with robust genetic influences on core mood and psychotic symptoms (primarily BD and SCZ PRS). These findings highlight the importance of considering transdiagnostic genetic risks in BD heterogeneity. It suggests early identification of psychosocial difficulties, especially with higher genetic burden for ADHD and anxiety, may improve long-term outcomes. Future research should prioritise longitudinal studies and biological mechanism investigations, focusing on observed nuanced relationships between symptoms and genetic contributions.

Supplementary Material

Supplementary.docx

Data availability

The data that support the findings of this study are available from the corresponding author, AM, upon reasonable request.

Research Material Availability

Summary statistics for the GWAS used here are publicly available to other researchers for download.

Analytic Code Availability

Analytic code supporting the findings are available to other researchers on request.

Author Contribution

Author TV led the design and writing of the manuscript. Author AM supported the statistical analyses. All authors, including NB contributed to revisions of the manuscript for the final submission.

Funding sources

This work was supported by the Stanley Center for Psychiatric Research at the Broad Institute for the genotyping of the control samples. Authors AM and NB were supported by the UCLH NIHR BRC. Author TV is supported in part by the National Institutes of Health (NIH) Graduate Partnership Program (GPP).

Ethical approval

The data collection procedures were approved by the NHS Metropolitan Multi-centre Research Ethics Committee (MREC/03/11/090).

Declaration of Interest

Declaration of Interest: None

Declaration of Generative AI and AI assisted technologies in the writing process.

No AI (artificial intelligence) and AI-assisted technologies were used in the writing process or statistical analyses.

Acknowledgements

The participants' genetic and clinical data was collected with support from, the Neuroscience Research Charitable Trust, the Central London NHS (National Health Service) Blood Transfusion Service, the Camden and Islington NHS Foundation Trust, a research lectureship from the Priory Hospitals and the National Institutes for Health Research (NIHR) Mental Health Research Network (MHRN).

Transparency Declaration

I, TV, affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Author Details

Correspondence email: a.mcquillin@ucl.ac.uk

References

1. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry [Internet]. 2013 Jun [cited 2025 Feb 9];12(2):92. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3683251/
2. Williams J, Farmer AE, Ackenheil M, Kaufmann CA, McGuffin P. A multicentre inter-rater reliability study using the OPCRIT computerized diagnostic system. Psychol Med [Internet]. 1996 [cited 2025 Jan 31];26(4):775–83. Available from: https://www.cambridge.org/core/journals/psychological-medicine/article/abs/multicentre-interrater-reliability-study-using-the-opcrit-computerized-diagnostic-system/C7E7B2428E757E37994BF0BD1B3B7B4A
3. Miskowiak KW, Hansen KB, Mariegaard J, Kessing LV. Association between childhood trauma, cognition, and psychosocial function in a large sample of partially or fully remitted patients with bipolar disorder and healthy participants. Int J Bipolar Disord [Internet]. 2023 Dec 1 [cited 2025 Jan 31];11(1):1–11. Available from: https://journalbipolardisorders.springeropen.com/articles/10.1186/s40345-023-00311-w
4. Grunze H, Born C. The Impact of Subsyndromal Bipolar Symptoms on Patient's Functionality and Quality of Life. Front Psychiatry [Internet]. 2020 Jun 12 [cited 2025 Jan 31];11:522126. Available from: www.frontiersin.org
5. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord. 2006 Jul 1;93(1–3):105–15. https://doi.org/10.1016/j.jad.2006.02.016
6. Sparding T, Pålsson E, Joas E, Hansen S, Landén M. Personality traits in bipolar disorder and influence on outcome. BMC Psychiatry [Internet]. 2017 May 3 [cited 2025 Jan 31];17(1):1–10. Available from: https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-017-1332-0
7. Schulze TG. Genetic research into bipolar disorder: the need for a research framework that integrates sophisticated molecular biology and clinically informed phenotype characterization. Psychiatr Clin North Am [Internet]. 2010 Mar [cited 2025 Feb 23];33(1):67–82. Available from: https://pubmed.ncbi.nlm.nih.gov/20159340/
8. Ruderfer DM, Fanous AH, Ripke S, McQuillin A, Amdur RL, Gejman PV, et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry. 2014;19:1017–24. https://pubmed.ncbi.nlm.nih.gov/24280982/

9. Coombes BJ, Markota M, Mann JJ, Colby C, Stahl E, Talati A, et al. Dissecting clinical heterogeneity of bipolar disorder using multiple polygenic risk scores. Transl Psychiatry [Internet]. 2020/09/20. 2020;10(1):314. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501305/pdf/41398_2020_Article_996.pdf

10. O'Connell KS, Coombes BJ. Genetic contributions to bipolar disorder: current status and future directions. Psychol Med [Internet]. 2021 Apr 21;1–12. Available from: https://www.cambridge.org/core/product/identifier/S0033291721001252/type/journal_article

11. Saunders EH, Scott LJ, McInnis MG, Burmeister M. Familiality and diagnostic patterns of subphenotypes in the National Institutes of Mental Health Bipolar sample. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics [Internet]. 2008 Jan 5 [cited 2025 Jan 21];147B(1):18–26. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.b.30558

12. Allardyce J, Leonenko G, Hamshere M, Pardiñas AF, Forty L, Knott S, et al. Association between schizophrenia-related polygenic liability and the occurrence and level of mood-incongruent psychotic symptoms in bipolar disorder. JAMA Psychiatry. 2018 Jan 1;75(1):28–35. https://doi.org/10.1001/jamapsychiatry.2017.3485

13. Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell [Internet]. 2018 Jun 16 [cited 2025 Feb 23];173(7):1705-15. e16. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29906448

14. Grigoroiu-Serbanescu M, van der Veen T, Bigdeli T, Herms S, Diaconu CC, Neagu AI, et al. Schizophrenia polygenic risk scores, clinical variables and genetic pathways as predictors of phenotypic traits of bipolar I disorder. J Affect Disord. 2024 Jul 1;356:507–18. https://doi.org/10.1016/j.jad.2024.04.066

15. Allardyce J, McCreadie RG, Morrison G, van Os J. Do symptom dimensions or categorical diagnoses best discriminate between known risk factors for psychosis? Soc Psychiatry Psychiatr Epidemiol [Internet]. 2007 Jul 14 [cited 2025 Jan 31];42(6):429–37. Available from: https://link.springer.com/article/10.1007/s00127-007-0179-y

16. Reininghaus U, Böhnke JR, Hosang G, Farmer A, Burns T, McGuffin P, et al. Evaluation of the validity and utility of a transdiagnostic psychosis dimension encompassing schizophrenia and bipolar disorder. The British Journal of Psychiatry [Internet]. 2016 Aug 1 [cited 2025 Jan 31];209(2):107–13.

Available from: https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/evaluation-of-the-validity-and-utility-of-a-transdiagnostic-psychosis-dimension-encompassing-schizophrenia-and-bipolar-disorder/9D25265627501197940E3DEF978FE81E

17. Legge SE, Cardno AG, Allardyce J, Dennison C, Hubbard L, Pardiñas AF, et al. Associations Between Schizophrenia Polygenic Liability, Symptom Dimensions, and Cognitive Ability in Schizophrenia. JAMA Psychiatry [Internet]. 2021 Aug 4 [cited 2021 Aug 14]; Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2782769

18. Richards AL, Cardno A, Harold G, Craddock NJ, Di Florio A, Jones L, et al. Genetic Liabilities Differentiating Bipolar Disorder, Schizophrenia, and Major Depressive Disorder, and Phenotypic Heterogeneity in Bipolar Disorder. JAMA Psychiatry [Internet]. 2022 Oct 1 [cited 2025 Jan 21];79(10):1032–9. Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795950

19. Allardyce J, Cardno AG, Gordon-Smith K, Jones L, Di Florio A, Walters JTR, et al. Specificity of polygenic signatures across symptom dimensions in bipolar disorder: an analysis of UK Bipolar Disorder Research Network data. Lancet Psychiatry [Internet]. 2023 Aug 1 [cited 2025 Jan 31];10(8):623–31. Available from: http://www.thelancet.com/article/S2215036623001864/fulltext

20. Krug A, Stein F, David FS, Schmitt S, Brosch K, Pfarr JK, et al. Factor analysis of lifetime psychopathology and its brain morphometric and genetic correlates in a transdiagnostic sample. Translational Psychiatry 2024 14:1 [Internet]. 2024 Jun 3 [cited 2025 Mar 4];14(1):1–10. Available from: https://www.nature.com/articles/s41398-024-02936-6

21. Oliva V, Fico G, De Prisco M, Gonda X, Rosa AR, Vieta E. Bipolar disorders: an update on critical aspects. The Lancet Regional Health - Europe [Internet]. 2025 Jan 1 [cited 2025 Mar 1];48:101135. Available from: https://www.thelancet.com/action/showFullText?pii=S2666776224003041

22. Sanches M, Bauer IE, Galvez JF, Zunta-Soares GB, Soares JC. The Management of Cognitive Impairment in Bipolar Disorder: Current Status and Perspectives. Am J Ther [Internet]. 2015 [cited 2025 Mar 1];22(6):477. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4424179/

23. Bennett F, Hodgetts S, Close A, Frye M, Grunze H, Keck P, et al. Predictors of psychosocial outcome of bipolar disorder: data from the Stanley Foundation Bipolar Network. Int J Bipolar Disord [Internet]. 2019 Dec 1 [cited 2025 Jan 28];7(1):1–9. Available from: https://journalbipolardisorders.springeropen.com/articles/10.1186/s40345-019-0169-5

24. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, et al. Psychosocial Disability in the Course of Bipolar I and II Disorders: A Prospective, Comparative, Longitudinal Study. Arch Gen Psychiatry [Internet]. 2005 Dec 1 [cited 2025 Mar 1];62(12):1322–30. Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/209110

25. Carballo JJ, Llorente C, Kehrmann L, Flamarique I, Zuddas A, Purper-Ouakil D, et al. Psychosocial risk factors for suicidality in children and adolescents. Eur Child Adolesc Psychiatry [Internet]. 2019 Jun 1 [cited 2025 Feb 24];29(6):759. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7305074/

26. Scott J, Graham A, Yung A, Morgan C, Bellivier F, Etain B. A systematic review and meta-analysis of delayed help-seeking, delayed diagnosis and duration of untreated illness in bipolar disorders. Acta Psychiatr Scand [Internet]. 2022 Nov 1 [cited 2025 Mar 1];146(5):389–405. Available from: https://pubmed.ncbi.nlm.nih.gov/36018259/

27. Dong M, Lu L, Zhang L, Zhang Q, Ungvari GS, Ng CH, et al. Prevalence of suicide attempts in bipolar disorder: a systematic review and meta-analysis of observational studies. Epidemiol Psychiatr Sci [Internet]. 2020 [cited 2025 Mar 1];29:e63. Available from: https://www.cambridge.org/core/journals/epidemiology-and-psychiatric-sciences/article/prevalence-of-suicide-attempts-in-bipolar-disorder-a-systematic-review-and-metaanalysis-of-observational-studies/494471CA6E53CECADA92AAF9246FDC5F

28. Lawrence JM, Breunig S, Foote IF, Tallis CB, Grotzinger AD. Genomic SEM applied to explore etiological divergences in bipolar subtypes. Psychol Med [Internet]. 2024 Apr 27 [cited 2025 Jan 21];54(6):1152–9. Available from: https://www.cambridge.org/core/journals/psychological-medicine/article/genomic-sem-applied-to-explore-etiological-divergences-in-bipolar-subtypes/0F464BA6422F3E3B907689B5FB3C7074

29. Léda-Rêgo G, Studart-Bottó P, Abbade P, Rabelo-Da-Ponte FD, Casqueiro JS, Sarmento S, et al. Lifetime prevalence of psychiatric comorbidities in patients with bipolar disorder: A systematic review and meta-analysis. Psychiatry Res [Internet]. 2024 Jul 1 [cited 2025 Mar 1];337. Available from: https://pubmed.ncbi.nlm.nih.gov/38763079/

30. Schoeler T, Choi SW, Dudbridge F, Baldwin J, Duncan L, Cecil CM, et al. Multi–Polygenic Score Approach to Identifying Individual Vulnerabilities Associated With the Risk of Exposure to Bullying.

JAMA Psychiatry [Internet]. 2019 Jul 1 [cited 2021 Aug 30];76(7):730–8. Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2729424

31. Aas M, Bellivier F, Bettella F, Henry C, Gard S, Kahn JP, et al. Childhood maltreatment and polygenic risk in bipolar disorders. Bipolar Disord. 2020 Mar 1;22(2):174–81. https://doi.org/10.1111/bdi.12851

32. Park YM, Shekhtman T, Kelsoe JR. Interaction between adverse childhood experiences and polygenic risk in patients with bipolar disorder. Transl Psychiatry. 2020 Dec 1;10(1). https://doi.org/10.1038/s41398-020-01010-1

33. Baldwin JR, Caspi A, Meehan AJ, Ambler A, Arseneault L, Fisher HL, et al. Population vs Individual Prediction of Poor Health From Results of Adverse Childhood Experiences Screening. https://doi.org/10.1001/jamapediatrics.2020.5602

34. Yao K, van der Veen T, Thygesen J, Bass N, McQuillin A. Multiple psychiatric polygenic risk scores predict associations between childhood adversity and bipolar disorder. J Affect Disord [Internet]. 2023 Nov 15 [cited 2025 Jan 31];341:137–46. Available from: https://pubmed.ncbi.nlm.nih.gov/37643680/

35. Kupka RW, Luckenbaugh DA, Post RM, Suppes T, Altshuler LL, Keck PE, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. American Journal of Psychiatry [Internet]. 2005 Jul [cited 2025 Jan 31];162(7):1273–80. Available from: https://psychiatryonline.org/doi/10.1176/appi.ajp.162.7.1273

36. Coryell W, Solomon D, Turvey C, Keller M, Leon AC, Endicott J, et al. The Long-term Course of Rapid-Cycling Bipolar Disorder. Arch Gen Psychiatry [Internet]. 2003 Sep 1 [cited 2022 Sep 26];60(9):914–20. Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/207789

37. Agnew-Blais JC, Belsky DW, Caspi A, Danese A, Moffitt TE, Polanczyk G V., et al. Polygenic Risk and the Course of Attention-Deficit/Hyperactivity Disorder From Childhood to Young Adulthood: Findings From a Nationally Representative Cohort. J Am Acad Child Adolesc Psychiatry [Internet]. 2021 Sep 1 [cited 2025 Mar 3];60(9):1147–56. Available from: https://www.jaacap.org/action/showFullText?pii=S0890856721000010

38. Patel KHS, Walters GB, Stefánsson H, Stefánsson K, Degenhardt F, Nothen M, et al. Predicting ADHD in alcohol dependence using polygenic risk scores for ADHD. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2024 Jun 1;195(4). https://doi.org/10.1002/ajmg.b.32967

39. Du Rietz E, Coleman J, Glanville K, Choi SW, O'Reilly PF, Kuntsi J. Association of Polygenic Risk for Attention-Deficit/Hyperactivity Disorder With Co-occurring Traits and Disorders. Biol Psychiatry

Cogn Neurosci Neuroimaging [Internet]. 2018 Jul 1 [cited 2025 Mar 3];3(7):635–43. Available from: https://pubmed.ncbi.nlm.nih.gov/30047479/

40. van Hulzen KJE, Scholz CJ, Franke B, Ripke S, Klein M, McQuillin A, et al. Genetic Overlap Between Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder: Evidence From Genome-wide Association Study Meta-analysis. Biol Psychiatry [Internet]. 2016/11/29. 2017;82(9):634–41. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027938/pdf/nihms-1553082.pdf

41. Grigoroiu-Serbanescu M, Giaroli G, Thygesen JH, Shenyan O, Bigdeli TB, Bass NJ, et al. Predictive power of the ADHD GWAS 2019 polygenic risk scores in independent samples of bipolar patients with childhood ADHD. J Affect Disord. 2020 Mar 15;265:651–9.

42. Coombes BJ, Millischer V, Batzler A, Larrabee B, Hou L, Papiol S, et al. Association of Attention-Deficit/Hyperactivity Disorder and Depression Polygenic Scores with Lithium Response: A Consortium for Lithium Genetics Study. Complex Psychiatry [Internet]. 2021 Dec 2 [cited 2025 Jan 31];7(3–4):80–9. Available from: https://dx.doi.org/10.1159/000519707

43. Lin Y, Maihofer AX, Stapp E, Ritchey M, Alliey-Rodriguez N, Anand A, et al. Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar Disord. 2021 Dec 1;23(8):821–31. https://doi.org/10.1111/bdi.13078

44. Allardyce J, Cardno AG, Gordon-Smith K, Jones L, Di Florio A, Walters JTR, et al. Specificity of polygenic signatures across symptom dimensions in bipolar disorder: an analysis of UK Bipolar Disorder Research Network data. Lancet Psychiatry [Internet]. 2023 Aug 1 [cited 2025 Jan 21];10(8):623–31. Available from: http://www.thelancet.com/article/S2215036623001864/fulltext

45. Robins J. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. Mathematical Modelling. 1986 Jan 1;7(9–12):1393–512.

46. Wang Y, Tsuo K, Kanai M, Neale BM, Martin AR. Challenges and Opportunities for Developing More Generalizable Polygenic Risk Scores. 2022 [cited 2025 Feb 26]; Available from: https://doi.org/10.1146/annurev-biodatasci-111721-07483047.

47. Mitchell RE, Hartley AE, Walker VM, Gkatzionis A, Yarmolinsky J, Bell JA, et al. Strategies to investigate and mitigate collider bias in genetic and Mendelian randomisation studies of disease progression. PLoS Genet [Internet]. 2023 Feb 23 [cited 2025 Jan 31];19(2):e1010596. Available from: https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1010596

48. Joreskog KG, Goldberger AS. Estimation of a Model with Multiple Indicators and Multiple Causes of a Single Latent Variable. J Am Stat Assoc. 1975 Sep;70(351):631.

49. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J [Internet]. 2014 Aug 1 [cited 2025 Mar 2];35(29):1925–31. Available from: https://pubmed.ncbi.nlm.nih.gov/24898551/

50. Lee S, Tsang A, Kessler RC, Jin R, Sampson N, Andrade L, et al. Rapid-cycling bipolar disorder: cross-national community study. British journal of psychiatry. 196(3):217–25. https://doi.org/10.1192/bjp.bp.109.067843

51. Rohde P, Lewinsohn PM, Seeley JR, Klein DN, Andrews JA, Small JW. Psychosocial Functioning of Adults who Experienced Substance Use Disorders as Adolescents. Psychol Addict Behav [Internet]. 2007 Jun [cited 2025 Mar 2];21(2):155. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2536752/

52. R Core Team (2024). R: A language and environment for statistical computing [Internet]. 2024 [cited 2025 Feb 1]. Available from: https://www.R-project.org/

53. Rosseel Y. lavaan: An R Package for Structural Equation Modeling. J Stat Softw [Internet]. 2012 May 24 [cited 2025 Feb 1];48:1–36. Available from: https://www.jstatsoft.org/index.php/jss/article/view/v048i02

54. Post RM, Kalivas P. BIPOLAR DISORDER AND SUBSTANCE ABUSE: PATHOLOGICAL AND THERAPEUTIC IMPLICATIONS OF THEIR COMORBIDITY AND CROSS SENSITIZATION. Biol Psychiatry. 1997 Nov 15;42(10):778-85. https://doi.org/10.1192/bjp.bp.112.116855

55. McMahon FJ. Prediction of treatment outcomes in psychiatry--where do we stand□? Dialogues Clin Neurosci [Internet]. 2014 [cited 2025 Mar 2];16(4):455–64. Available from: https://pubmed.ncbi.nlm.nih.gov/25733951/

56. Carey CE, Shafee R, Wedow R, Elliott A, Palmer DS, Compitello J, et al. Principled distillation of UK Biobank phenotype data reveals underlying structure in human variation. Nature Human Behaviour 2024 8:8 [Internet]. 2024 Jul 4 [cited 2025 Jan 31];8(8):1599–615. Available from: https://www.nature.com/articles/s41562-024-01909-5

57. Song J, Jonsson L, Lu Y, Bergen SE, Karlsson R, Smedler E, et al. Key subphenotypes of bipolar disorder are differentially associated with polygenic liabilities for bipolar disorder, schizophrenia, and

major depressive disorder. Molecular Psychiatry 2024 29:7 [Internet]. 2024 Feb 14 [cited 2025 Jan 21];29(7):1941–50. Available from: https://www.nature.com/articles/s41380-024-02448-1

58. Duffy A. The nature of the association between childhood ADHD and the development of bipolar disorder: A review of prospective high-risk studies. American Journal of Psychiatry [Internet]. 2012 Dec 1 [cited 2025 Feb 1];169(12):1247–55. Available from: https://psychiatryonline.org/doi/10.1176/appi.ajp.2012.11111725

59. Vannucchi G, Medda P, Pallucchini A, Bertelli M, Angst J, Azorin JM, et al. The relationship between attention deficit hyperactivity disorder, bipolarity and mixed features in major depressive patients: Evidence from the BRIDGE-II-Mix Study. J Affect Disord. 2019 Mar 1;246:346–54. https://doi.org/10.1016/j.jad.2018.12.089

60. Guzman-Parra J, Streit F, Forstner AJ, Strohmaier J, Gonzalez MJ, Gil Flores S, et al. Clinical and genetic differences between bipolar disorder type 1 and 2 in multiplex families. Transl Psychiatry [Internet]. 2021/01/13. 2021;11(1):31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33431802

61. Mignogna KM, Goes FS. Characterizing the longitudinal course of symptoms and functioning in bipolar disorder. Psychol Med [Internet]. 2024 Jan 14 [cited 2025 Feb 1];54(1):79–89. Available from: https://www.cambridge.org/core/journals/psychological-medicine/article/characterizing-the-longitudinal-course-of-symptoms-and-functioning-in-bipolar-disorder/07D66C01AB55D5B5DA97D166A8E2C891

62. Qiu F, Akiskal HS, Kelsoe JR, Greenwood TA. Factor analysis of temperament and personality traits in bipolar patients: Correlates with comorbidity and disorder severity. J Affect Disord. 2017 Jan 1;207:282–90. https://doi.org/10.1016/j.jad.2016.08.031

63. Salvi V, Ribuoli E, Servasi M, Orsolini L, Volpe U. ADHD and Bipolar Disorder in Adulthood: Clinical and Treatment Implications. Medicina (B Aires) [Internet]. 2021 May 1 [cited 2022 Aug 2];57(5). https://doi.org/10.3390/medicina57050466

64. Miller CJ, Flory JD, Miller SR, Harty SC, Newcorn JH, Halperin JM. Childhood ADHD and the Emergence of Personality Disorders in Adolescence: A Prospective Follow-up Study. J Clin Psychiatry [Internet]. 2008 [cited 2025 Mar 3];69(9):1477. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2637402/

65. Birmaher B, Axelson D, Goldstein B, Monk K, Kalas C, Obreja M, et al. Psychiatric Disorders in Preschool Offspring of Parents with Bipolar Disorder: The Pittsburgh Bipolar Offspring Study (BIOS). Am J Psychiatry [Internet]. 2010 Mar [cited 2025 Mar 4];167(3):321. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2868596/

66. McClelland H, Cleare S, O'Connor RC. Suicide Risk in Personality Disorders: A Systematic Review. Curr Psychiatry Rep [Internet]. 2023 Sep 1 [cited 2025 Mar 4];25(9):405. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10506938/

67. Meier, S. M., Pavlova, B., Dalsgaard, S., Nordentoft, M., Mors, O., Mortensen, P. B., & Uher, R. (2018). Attention-deficit hyperactivity disorder and anxiety disorders as precursors of bipolar disorder onset in adulthood. *The British journal of psychiatry : the journal of mental science*, *213*(3), 555–560. https://doi.org/10.1192/bjp.2018.111

68. Nunez, N. A., Coombes, B. J., Romo-Nava, F., Bond, D. J., Vande Voort, J., Croarkin, P. E., Leibman, N., Gardea Resendez, M., Veldic, M., Betcher, H., Singh, B., Colby, C., Cuellar-Barboza, A., Prieto, M., Moore, K. M., Ozerdem, A., McElroy, S. L., Frye, M. A., & Biernacka, J. M. (2022). Clinical and Genetic Correlates of Bipolar Disorder With Childhood-Onset Attention Deficit Disorder. *Frontiers in psychiatry*, *13*, 884217. https://doi.org/10.3389/fpsyt.2022.884217